Please login to the form below

Not currently logged in
Email:
Password:

Dr Richard Barker joins Celgene's board of directors

Former ABPI director general takes up second new post this month

Richard Barker - CelgeneFormer director general of the Association of the British Pharmaceutical Industry (ABPI) Dr Richard Barker has been elected to the board of directors at Celgene.

He spent almost seven years at ABPI's helm, stepping down in May last year when he was succeeded by Stephen Whitehead.

It is Barker's second recent appointment after he joined authentication and traceability services company Aegate earlier this month as a senior adviser.

Prior to his post leading the ABPI, Barker's career included serving as chief executive of Chiron Diagnostics, general manager of IBM's Worldwide Healthcare Solutions division and leader of McKinsey & Company's European healthcare practice.

Robert Hugin, Celgene's chairman and CEO, said: “As we continue to expand our global reach, Dr Barker's international perspective will enhance our ability to navigate through an increasingly dynamic healthcare landscape and provide patients access to our innovative therapies.”

The US biopharmaceutical company focuses on developing and commercialising novel treatments for cancer and inflammatory diseases.

Its top-selling product is Revlimid, which suffered a setback last November after a phase III prostate cancer trial found no overall survival benefit.

Nevertheless, the drug is still expected to account for around $3bn of the firm's 2011 sales.

24th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics